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Appropriate termination of regenerative processes
is critical for producing the correct number of cells
in tissues. Here we provide evidence for an end-
product inhibition of dopamine neuron regeneration
that is mediated by dopamine. Ablation of midbrain
dopamine neurons leads to complete regeneration
in salamanders. Regeneration involves extensive
neurogenesis and requires activation of quiescent
ependymoglia cells, which express dopamine recep-
tors. Pharmacological compensation for dopamine
loss by L-dopa inhibits ependymoglia proliferation
and regeneration in a dopamine receptor-signaling-
dependent manner, specifically after ablation of
dopamine neurons. Systemic administration of the
dopamine receptor antagonist haloperidol alone
causes ependymoglia proliferation and the appear-
ance of excessive number of neurons. Our data
show that stem cell quiescence is under dopamine
control and provide a model for termination once
normal homeostasis is restored. The findings estab-
lish a role for dopamine in the reversible suppression
of neurogenesis in themidbrain andhave implications
for regenerative strategies in Parkinson’s disease.
INTRODUCTION
Local stem and progenitor cells are targets for promoting regen-
eration (Lindvall et al., 2004), for which it is critical to understand
how they sense the extent of cell loss in relation to the normal
homeostatic turnover. An insufficient regenerative response or
a rampant regeneration process could result either in an incom-
plete or superfluous number of cells. Therefore, two critical steps
to regulate are the initiation and appropriate termination of the
generation of new cells. However, very little is known about
the mechanisms that control the duration of replacement after
cell loss, particularly in otherwise essentially quiescent tissues.
We addressed these questions by studying the regeneration of
dopamine neurons in the midbrain of an adult salamander, the
red spotted newt. Newts are powerful models that possess the
most extensive regenerative capacities among adult vertebrates426 Cell Stem Cell 8, 426–433, April 8, 2011 ª2011 Elsevier Inc.(Brockes and Kumar, 2005) and their dopaminergic system has
been well characterized (Gonzalez and Smeets, 1994).
After chemical ablation of midbrain dopamine neurons by
6-OHDA (Figures 1A–1D; Parish et al., 2007), regeneration in
salamanders leads to complete histological restoration and to
full recovery of motor behavior (Parish et al., 2007). To date,
the salamander provides the sole available animal model that
allows discovery of principles of robust midbrain dopamine neu-
rogenesis in a Parkinson’s disease-like condition. Dopaminergic
regeneration depends on cellular proliferation and is character-
ized by cell cycle reentry of ependymoglia stem cells (Benraiss
et al., 1996; Echeverri and Tanaka, 2002; McHedlishvili et al.,
2007) lining the ventricle in the normally quiescent midbrain
(Parish et al., 2007). Dopamine neurons, which express the
evolutionarily conserved markers tyrosine hydroxylase (TH)
and Nurr1, are born gradually during regeneration and reach
normal numbers within 4 weeks after ablation (Parish et al.,
2007). No new dopamine neurons are detected in the midbrain
of control animals (Berg et al., 2010); conversely no excessive
neurons are formed after full recovery (Figure S1A available
online; Parish et al., 2007).
RESULTS
We asked whether a driving force for dopamine neuron regener-
ation is the reduced level of dopamine after ablation of the
neurons by which dopamine is produced. To test this possibility,
we treated 6-OHDA-ablated animals with L-3,4-dihydroxyphe-
nylalanine (L-dopa), which is a widely used substance for phar-
macological compensation therapy in patients with Parkinson’s
disease (Goetz et al., 2005). L-dopa is a precursor of dopamine,
which can cross the blood-brain barrier and is converted to
dopamine by the remaining dopamine neurons (Carlsson et al.,
2007). Animals received intraperitoneal injections of L-dopa for
6 days, starting either 2 days or 9 days after chemical ablation
(Figures 1A–1D). L-dopa administration inhibited the recovery
of TH+ and Nurr1+ neurons. Recovery of TH+ neurons was
reduced by 78% after L-dopa administration between days 2
and 8 (Figure 1E) and by 35% after L-dopa administration
between days 9 and 15 (Figure 1H; Figure S2A). In accordance
with this, the number of cells expressing Nurr1, which is found
in the precursors and in fully differentiated dopamine neurons
(Parish et al., 2007), was reduced by 32% after L-dopa adminis-
tration between days 2 and 8 (Figure 1F) and by 34% after
L-dopa administration between days 9 and 15 (Figure 1I).
Figure 1. Pharmacological Compensation
for Dopamine Loss Specifically Inhibits the
Regeneration of Dopamine Neurons in the
Midbrain
(A–D) Ablation of midbrain DA neurons revealed
by the loss of TH- and Nurr1-expressing neurons
(B, D) compared to control brains (A, C).
(E–G) L-dopa administration between days 2 and 8
inhibits the regeneration of TH+ (E) and Nurr1+ (F)
neurons as well as locomotor recovery (G).
(H and I) L-dopa administration between days 9
and 15 inhibits the regeneration of TH+ (H) and
Nurr1+ (I) neurons.
(J) L-dopa administration does not inhibit regener-
ation of ChAT+ neurons.
(K) The GABAA receptor agonist muscimol does
not inhibit regeneration of TH+ neurons in the
midbrain.
n = 3–16 for each group. Error bars represent SEM.
Ve indicates the third ventricle. Scale bars repre-
sent 50 mm. See also Figure S1 and Movie S1.
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performance was also reduced by 40% in L-dopa-treated
animals assessed 1 day after the termination of L-dopa adminis-
tration (Figure 1G). We saw that L-dopa administration in nonle-
sioned animals did not influence the locomotor performance
1 day after drug removal (Movie S1).
Next, we ablated cholinergic neurons in themidbrain by inject-
ing ethylcholine aziridinium (AF64A) (Harms et al., 2007; Rinner
et al., 1997). Cholinergic neurons were identified by the expres-
sion of choline acetyltransferase (ChAT) (Figures S1B–S1D).
Regeneration of cholinergic neurons was gradual and took
7 weeks (Figures S1E–S1G). In contrast to the regeneration of
dopamine neurons after 6-OHDA injection, L-dopa administra-
tion between days 9 and 15 after AF64A injection did not influ-
ence the regeneration of cholinergic neurons (Figure 1J).Cell Stem Cell 8, 426–Next we treated animals with high
doses of the g-aminobutyric acid
(GABA)A receptor agonist muscimol
between days 9 and 15 after ablation. In
contrast to L-dopa, muscimol had no
effect on the regeneration of TH+ neurons
(Figure 1K; Figure S2B).
These results together show that phar-
macological compensation for dopamine
loss specifically inhibits dopamine neuron
regeneration.
Several studies indicated that neuro-
transmitters including dopamine may
influence neurogenesis by modulating
stem and progenitor cell proliferation,
differentiation, precursor migration, sur-
vival, and functional integrationof neurons
(Ge et al., 2007;Ho¨glinger et al., 2004;Kim
et al., 2006; Kippin et al., 2005; Liu et al.,
2005; O’Keeffe et al., 2009). L-dopa
administration did not alter the number
of TUNEL+/TH+ cells, indicating that itdoes not influence neuronal survival (data not shown). We tested
how L-dopa administration modulated the proliferation of epen-
dymoglia cells, which line the brain ventricles. We found that
ependymoglia cell proliferation in ablated animals was reduced
by 82% by L-dopa in the midbrain (Figures 2A–2C; Figure S2C)
as revealed by double immunostaining for the proliferating cell
nuclear antigen (PCNA) and the intermediate filament protein
GFAP. L-dopa administration did not reduce the increased epen-
dymoglia proliferation caused by the ablation of cholinergic
neurons in the midbrain (Figure 2C). This is consistent with the
observation that regeneration of cholinergic neurons was not
reduced by L-dopa treatment (Figure 1J). No significant modula-
tion of ependymoglia proliferation was seen after sham ablation
(Figure 2C) or after treatment with the GABAA receptor agonist
muscimol (Figure 2D; Figure S2D). Furthermore, L-dopa433, April 8, 2011 ª2011 Elsevier Inc. 427
Figure 2. Pharmacological Compensation for Dopamine Loss Inhibits Midbrain Ependymoglia Cell Proliferation Specifically after Ablation
of Dopamine Neurons
(A–C) L-dopa administration reduces the number of proliferating midbrain ependymoglia cells (B) compared to controls (A) in 6-OHDA-injected animals, but
proliferation is not reduced in sham-injected animals or after cholinergic ablation (C).
(D) The GABAA receptor agonist muscimol does not modulate ependymoglia proliferation after ablation of dopamine neurons.
(E) L-dopa administration has no effect on the ablation-independent proliferation of forebrain ependymoglia cells.
(F–H) Dopamine reduces the proliferation of ependymoglia cells in vitro.
n = 3–16 for each group. Error bars represent SEM. Ve indicates the third ventricle. Scale bar represents 50 mm. See also Figure S2.
Cell Stem Cell
Dopamine Control of Midbrain Neurogenesisadministration had no effect on the ablation-independent, contin-
uously ongoing proliferation of forebrain ependymoglia cells that
line the lateral ventricles (Figure 2E). To test whether dopamine is
able to directly regulate ependymoglia cell proliferation, we
treated monolayer cultures of ependymoglia cells that line the
third ventricle with dopamine. Ependymoglia cells are stem cells
in the newtCNSand the only cell type that expressesGFAP given
the lack of astrocytes (Figure S3A; Benraiss et al., 1996; Lazzari
et al., 1997). Dopamine inhibited proliferation, as revealed by428 Cell Stem Cell 8, 426–433, April 8, 2011 ª2011 Elsevier Inc.double immunostaining for GFAP and the nucleotide analog
BrdU that intercalates into the DNA during the S-phase of
the mitotic cell cycle and by the decreased number of GFAP-
expressing cells (Figures 2F–2H; Figure S2G). These results
show that dopamine can directly inhibit ependymoglia cell prolif-
eration and provide a rationale for the reduced dopaminergic
regeneration during L-dopa treatment.
Next we asked whether the inhibitory effect of L-dopa was
mediated through dopamine receptor signaling. Animals were
Figure 3. Dopamine Receptor Antagonism Restores Ependymoglia Proliferation and the Regeneration of TH+ Neurons
(A and B) Coadministration of the dopamine receptor antagonist haloperidol restores the L-dopa-caused reduction of midbrain ependymoglia proliferation (A)
and regeneration of TH+ neurons (B). n = 3–16 for each group. Error bars represent SEM.
(C–E) Many midbrain ependymoglia express D2R.
(F, f, ff) Midbrain TH+ neurons are in close proximity to ependymoglia cells.
Ve indicates the third ventricle, DA (dopamine). Scale bars represent 50 mm. See also Figures S3 and S4 and Movie S2.
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Dopamine Control of Midbrain Neurogenesistreated with L-dopa alone or together with haloperidol, which is
a selective dopamine receptor antagonist (Jackson and West-
lind-Danielsson, 1994). The coadministration of haloperidol
largely restored both ependymoglia cell proliferation as well as
the regeneration of TH+ neurons (Figures 3A and 3B). However,
haloperidol treatment did not enhance the normal regeneration
process (Figures S2E and S2F). Consistent with the findings
that dopamine receptor signaling is required for suppression of
regeneration by L-dopa, we found that many ependymoglia cells
expressed D2 dopamine receptors (Figures 3C–3E). We found
that the D2 dopamine receptor is highly conserved during evolu-
tion, showing 75% identity at the amino acid level between
newts and humans (Figure S4). By using double immunostaining
of whole-mount specimens, we found that TH+ neurons are inclose proximity with the radial processes of ependymoglia cells
(Figures 3F–3ff; Movie S2), suggesting that ependymoglia cells
could be targets of previously described dendritic release of
dopamine by midbrain dopamine neurons (Cheramy et al.,
1981; Geffen et al., 1976).
Given the strong receptor signaling-dependent inhibitory effect
of dopamine on ependymoglia proliferation, we tested whether
antagonizing dopamine receptors alone is sufficient to evoke
cell cycle reentry by quiescent ependymoglia cells. Nonablated
animals received daily intraperitoneal injections of haloperidol
for 4 days (2 mg/kg/injection), for 8 days (1 mg/kg/injection), or
for 15 days (2 mg/kg/injection). While almost all cells in the adult
newt midbrain are quiescent with the exception of 3 ± 2 PCNA+
ependymoglia cell/midbrain (Figure 4A; Berg et al., 2010),Cell Stem Cell 8, 426–433, April 8, 2011 ª2011 Elsevier Inc. 429
Figure 4. Dopamine Receptor Antagonism Undermines Ependymoglia Quiescence and Causes the Appearance of Excessive Numbers of
Neurons
(A) Haloperidol administration evokes cell cycle reentry by normally quiescent midbrain ependymoglia cells.
(B and C) Haloperidol administration leads to the appearance of excessive numbers of Nurr1+ (B) and TH+ (C) neurons.
n = 3–5 for each group. Error bars represent SEM.
(D–G) Haloperidol administration results in newly formed Nurr1+ cells shown by BrdU+/Nurr1+ cells. Arrows point to Nurr1/BrdU cells, filled arrowheads point
to Nurr1+/BrdU- cells, arrowhead points to a BrdU+/Nurr1+ cell (E–G is the area indicated by the rectangle in D).
(H–K) Specific labeling of ependymoglia cells in vivo by electroporation. Expression of YFP is restricted to ependymoglia cells 24 hr after electroporation.
(L and M) Haloperidol administration results in the transition of ependymoglia to TH+ cells. Arrowhead points to an ependymoglia cell expressing YFP; arrow
points to a TH+ cell expressing YFP.
(N) Schematic model illustrating that loss of dopamine after ablation of its producing neurons lifts the proliferation block, allowing cells to enter a regenerative
program. Conversely, the regenerative process ends when normal dopaminergic homeostasis has been restored, and dopamine signaling is required for the
reversible suppression of neurogenesis in the adult newt midbrain.
Ve indicates the third ventricle, DA (dopamine). Scale bars represent 50 mm. See also Figure S3.
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Dopamine Control of Midbrain Neurogenesishaloperidol treatment caused their cell cycle reentry. Treatment
with haloperidol resulted in significant increase in the number of
PCNA+/GFAP+ cells (Figure 4A). Although the number of ependy-
moglia cells entering the cell cycle after a 4 day treatment with
2 mg/kg haloperidol corresponds to only 50% of the maximum
number of cycling ependymoglia cells after ablation of the dopa-
mine neurons, the results establish that dopamine receptor
signaling is critical in preventing ependymoglia proliferation.
To distinguish between D1 and D2 dopamine receptor
signaling, we treated animals with the selective D1 receptor
antagonist SCH23390 (O’Boyle andWaddington, 1987). Despite
the fact that that D1 and D2 receptors showed overlapping
expression pattern in themidbrain (Figures S3D–S3G), treatment
with SCH23390 had no effect on cell cycle reentry in themidbrain
(data not shown). In contrast, SCH23390 reducedmitotic activity
in a constitutively active proliferation hotspot, which is located
between the dorsal and lateral pallium in the forebrain (data
not shown; Berg et al., 2010).
We next tested whether haloperidol-mediated cell cycle
reentry ultimately causes the production of excessive number
of neurons. We found an increase in the number of Nurr1+ cells
in the midbrain after treatment for 4 days with 2 mg/kg haloper-
idol (Figure 4B). Furthermore, BrdU administration to haloper-
idol-treated animals revealed BrdU+/Nurr1+ cells, which are
never seen in control animals, indicating the presence of newly
formed Nurr1+ cells (Figures 4D–4G). We also counted the
number of TH+ neurons after haloperidol administration but we
did not notice a statistically significant increase in their number
after 4 days (data not shown). However, 15 days of haloperidol
administration at 2 mg/kg caused an increased number of TH
neurons, suggesting terminal differentiation of dopamine
neurons (Figure 4C). In order to further assess whether blocking
dopamine receptor signaling allows some ependymoglia cells to
produce TH+ neurons, we first expressed YFP in ventricular
ependymoglia cells by in vivo electropration and subsequently
treated animals with haloperidol. Electroporation of a YFP
construct resulted in specific labeling of ependymoglia cells
with 99.5% of the YFP-expressing cells being GFAP+ and
ventricular (Figures 4H–4K). We found a significant increase
(p = 0.008; Student’s t test) in the number of YFP+/TH+ cells after
haloperidol treatment. Although no YFP+/TH+ cells were found in
eight control animals, we detected in average 4.2 ± 1.5 TH+/
YFP+ cells in six animals that were treated with haloperidol
(Figures 4L and 4M). These results show that antagonizing dopa-
mine receptors allows the generation of new TH+ neurons from
activated ependymoglia cells.
DISCUSSION
A key step during midbrain dopamine neuron regeneration is the
cell cycle reentry of quiescent progenitors. Here we show that
dopamine receptor signaling is a critical gatekeeper for this
step. The model derived thereof suggests that loss of dopamine
after ablation of its producing neurons lifts the proliferation block,
allowing cells to enter a regenerative program. Conversely, the
regenerative process ends when normal dopaminergic homeo-
stasis has been restored, and dopamine signaling is required
for the reversible suppression of neurogenesis in the adult
newt midbrain (Figure 4N).The present data do not exclude the possibility that dopamine
influences stem and progenitor cell proliferation in other contexts
as well. However, several observations argue for dopamine
acting effectively in a feedback-likemanner in themidbrain. First,
increased dopamine levels inhibit ependymoglia proliferation as
well as dopaminergic regeneration specifically after ablation of
dopamine neurons but not after sham ablation. Second,
L-dopa administration does not modulate the ablation-indepen-
dent progenitor proliferation in the forebrain. Third, L-dopa
administration does not reduce cholinergic neuron regeneration
nor the increased ependymoglia proliferation caused by ablating
cholinergic neurons in themidbrain. Conversely, treating animals
with the GABAA receptor agonist muscimol does not inhibit
midbrain ependymoglia proliferation and dopaminergic regener-
ation after 6-OHDA injection. Fourth, dopamine neuron regener-
ation is rescued if dopamine receptor signaling is antagonized
while animals are treated with L-dopa. Fifth, dopamine receptor
antagonism is sufficient to evoke cell cycle reentry by progeni-
tors and to produce Nurr1+ and TH+ neurons.
In addition, the mammalian brain responds to the loss of
dopamine neurons by increased cell cycle reentry of progenitors
with the potential of dopaminergic differentiation (Lie et al.,
2002; Shan et al., 2006; Zhao et al., 2003). This observation
has two implications in the context of the present findings. First,
extensive production of new neurons in the mammalian
midbrain may not be curtailed at the level of mitotic activity of
progenitors but rather because of the lack of instructive cues,
which are reactivated in the adult newt brain (Berg et al.,
2010). Second, proliferation of progenitors may be under nega-
tive control of dopamine also in the mammalian midbrain. There-
fore, a direct implication of the data presented here is that
currently applied pharmacological compensation strategies in
Parkinson’s patients may have adverse effects on efforts of
promoting regeneration by stimulating neurogenesis in situ.
Implantation of dopamine neurons, which are generated
in vitro from stem and progenitors cells, is another promising
way for cell therapy (Friling et al., 2009; Parish et al., 2008).
The success of this strategy relies in part on the efficacy of
neuronal differentiation in vitro, which may be reduced by the
appearance of the neurons of interest. This knowledge may
contribute to refine existing or to develop new regenerative
strategies for Parkinson’s disease.
Previous investigations regarding the pro- and antimitotic
effect of dopamine on neural stem and progenitor cells resulted
in contradictory observations (e.g., Ho¨glinger et al., 2004; Kippin
et al., 2005; O’Keeffe et al., 2009), and the functional conse-
quence of cell cycle regulation by dopamine on neuron regener-
ation has remained difficult to explore. Our results establish
a dual role for dopamine by signaling not only to other differenti-
ated neurons but also to neuronal progenitors, thereby control-
ling neurogenesis. Such involvement of neurotransmitters could
be a plausible means linking the need for regeneration to the loss
of functionality in the central nervous system.
It has been proposed that secreted, antimitotic factors, so-
called chalones, control the size of adult tissues from which
they are derived (Bullough, 1965; Lander et al., 2009; Pellettieri
and Sa´nchez Alvarado, 2007). The present data suggest a selec-
tive aspect of a chalone-like function for dopamine, namely
the regulation of neuron number in an existing brain structure.Cell Stem Cell 8, 426–433, April 8, 2011 ª2011 Elsevier Inc. 431
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Animals and Procedures
Experiments were performed according to European Community and local
ethics committeeguidelines.Adult redspottednewtsNotopthalmusviridescens
(Charles Sullivan Co., Nashville, TN) were maintained in a humidified room
at 15C–20C. Ablation of the midbrain dopamine neurons was done by intra-
ventricular injection of 6-OHDA as previously described (Parish et al., 2007).
L-dopa or haloperidol were administered intraperitoneally by twice daily
injections. L-dopa/Carbidopa (Sigma) was administered at 50/12.5 mg/kg
dissolved in PBS. Haloperidol (Sigma) was dissolved in PBS and administered
at either 1 or 2 mg/kg. Control animals were injected with PBS. During haloper-
idol treatment, BrdU was administered intraperitoneally six times daily at
300 mg/kg. Cholinergic ablations were carried out according to Harms et al.
(2007) and Rinner et al. (1997) by intracranial injection of 20 ng AF64A.
Muscimol treatment was carried out by twice daily intraperitoneal injections
at 2 mg/kg between days 9 and 15 after 6-OHDA injection. SCH23390 was
injected at 1 mg/kg dissolved in PBS.
Assessment of Ablation and Regeneration
Regeneration of dopamine neurons was related to the degree of ablation,
which was assessed by behavioral performance as described in Parish et al.
(2007) or by counting the remaining TH- and Nurr1-expressing cells in the
midbrain of animals that were sacrificed 3 days after 6-OHDA injection
(n = 4/experiment). Ablation and regeneration of cholinergic neurons were
assessed by counting the ChAT-expressing neurons.
Antibodies and Staining Protocols
Animals were anesthetized with a solution of 0.1% MS-222 (Sigma) and
perfused with 4% formaldehyde in PBS. Animals were dissected and the
brains were postfixed for 1 hr in 4% formaldehyde and thereafter cryopro-
tected in 20% sucrose overnight. A 1:5 series of 20 mm coronal sections
were collected. Cultured cells were fixed in 4% formaldehyde for 5 min.
Sections and cultured cells were then incubated in PBS containing 0.1%
Triton-X for 15 min and rinsed in PBS, before being incubated in block solution
(PBS containing 0.1% Triton-X, 5% goat serum) and primary antibodies over-
night at 4C. The primary antibodies used were rabbit anti-TH (1:500, Chemi-
con), rabbit anti-Nurr1 (1:500, Santa Cruz Biotechnology), mouse anti-GFAP
(1:500, Sigma), rabbit anti-GFAP (1:500, Sigma), mouse anti-PCNA (1:500,
Chemicon), rat anti-BrdU (1:500, Accurate Chemical and Scientific Corpora-
tion), rabbit anti-D2 dopamine receptors (1:500, Millipore), goat anti-ChAT
(1:250, Millipore), and rabbit anti-D1 dopamine receptor (1:750, Millipore).
For BrdU and PCNA staining, sections and cells were treated with 2 M HCL/
0.5% Triton-X solution for 20 min at 37C followed by 2 M sodium tetraborate
for 5 min before antibody incubation. For D2 dopamine receptors antibody
staining, tissues were treated with 100% methanol for 10 min at 20C
followed by two washes in PBS before the primary antibody was applied.
The appropriate secondary antibodies (Molecular Probes) were applied in
blocking solution for 2 hr. Sections were mounted in mounting medium con-
taining 1 mg/ml Dapi (Dako). For whole-mount staining, animals were anesthe-
tized as above and brains were isolated and placed in PBS. The telencephalon
was removed and the midbrain and hindbrain were cut into two parts through
the center of the third ventricle. The lateral brain halves were fixed overnight in
4% PFA/0.1% Triton-X at 4C.
Primary Cell Culture
Brains were isolated and placed in ice-cold HBSS. The telencephalon and the
hindbrain were removed and the remaining tissue was dissociated in
1.33mg/ml trypsin in HBSS. Cells were centrifuged at 3003 g for 5min, resus-
pended in HBSS, and centrifuged at 3003 g for 5min. Cells were resuspended
in Neurobasal A medium supplemented with B27, Glutamax, EGF, and bFGF
at 10 ng/ml. Cells were plated on poly-D-lysine-coated culture slides (Becton
Dickinson). Dopamine (Sigma) and fresh media was added to the cells every
second day for 8 days. At day 9, 10 mM BrdU (Sigma) was added to the cells.
Microscopy and Image Analyses
Sections were observed under a Zeiss Axiskop2microscope and images were
acquired with a Zeiss camera with Openlab (Improvision) software. Images432 Cell Stem Cell 8, 426–433, April 8, 2011 ª2011 Elsevier Inc.were processed and complied with Adobe creative suite software. For
confocal microscopy, an LSM 510 Meta laser microscope with LSM 5 Image
Browser software (both Carl Zeiss MicroImaging, Inc.) was used. All images
were manipulated with Adobe Photoshop with linear adjustments.
In Vivo Electroporation
Electroporation was adapted from Barnabe´-Heider et al. (2008). In brief,
300–500 nl of 2–5 mg/ml of plasmid solution encoding H2BYFP under the
control of CMV promoter was injected into the third ventricle of the newts
and electroporated in a dorsal to ventral direction with a 175 V/cm pulse five
times for 50 ms each with a pause of 950 ms between each pulse.
Statistical Analyses
Student’s t test was used where p values are indicated.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and two movies and can be found with this article online at
doi:10.1016/j.stem.2011.02.001.
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